vidarabine has been researched along with Carcinoma, Merkel Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dave, SS; Kulbacki, E; McKinney, MS; Papalas, JA; Wang, E | 1 |
| Amir, G; Cohen, Y; Polliack, A | 1 |
2 other study(ies) available for vidarabine and Carcinoma, Merkel Cell
| Article | Year |
|---|---|
Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carcinoma, Merkel Cell; Cyclophosphamide; Diagnosis, Differential; Fatal Outcome; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Merkel cell polyomavirus; Neoplasms, Multiple Primary; Polyomavirus Infections; Rituximab; Skin Neoplasms; Tumor Virus Infections; Vidarabine | 2014 |
Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Carcinoma, Merkel Cell; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Rituximab; Salvage Therapy; Vidarabine | 2002 |